In human medicine, pentoxifylline has been used as an adjuvant medication for the treatment of pemphigus vulgaris since it has been shown to inhibit TNF‐alpha, playing a partial role in the pathogenesis of the disease (Didona et al., 2019; El‐Darouti et al., 2009; Frew et al., 2011; Tham et al., 2020; Zhao & Murrell, 2015). Here, TNF is linked to pemphigus vulgaris.